Indeed, anti-inflammatory [systemic lupus erythematosis (SLE), STING-associated vasculopathy with onset in infancy (SAVI), and Copa syndrome (COPA)], anti-viral (hepatitis and HIV) and anti-tumor treatments target type I IFN signaling. Here, STING1 is linked to neoplasm.